Remission Induction

• 

  Subject Areas on Research

  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. 
  • 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. 
  • 5-Azacitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-Dose Chemotherapy. 
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease. 
  • 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. 
  • A Brief Clinical Tool to Estimate Individual Patients' Risk of Depressive Relapse Following Remission: Proof of Concept. 
  • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 
  • A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness. 
  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. 
  • A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. 
  • A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. 
  • A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. 
  • A fidelity measure for integrated management of depression in primary care. 
  • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A naturalistic, multi-site study of repetitive transcranial magnetic stimulation therapy for depression. 
  • A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. 
  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. 
  • A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. 
  • A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. 
  • A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. 
  • A proportional hazards model for incidence and induced remission of disease. 
  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. 
  • A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. 
  • A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. 
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. 
  • Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis--a Pediatric Oncology Group Study. 
  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. 
  • Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. 
  • Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. 
  • Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. 
  • Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. 
  • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. 
  • Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. 
  • An evidence-based medicine strategy for achieving remission in bipolar disorder. 
  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. 
  • Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. 
  • Autologous bone marrow transplantation for acute lymphoblastic leukemia. 
  • Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. 
  • B cell loss leading to remission in severe systemic lupus erythematosus. 
  • BDNF Val66Met genotype and 6-month remission rates in late-life depression. 
  • Bariatric Surgery: A Potential Treatment for Type 2 Diabetes in Youth. 
  • Beyond prone position in percutaneous nephrolithotomy: a comprehensive review. 
  • Biologic predictors of clinical improvement in rituximab-treated refractory myositis. 
  • Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia. 
  • Bone marrow transplantation: what is the question? 
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 
  • Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. 
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 
  • CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. 
  • CYP2C19 variation and citalopram response. 
  • Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 
  • Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. 
  • Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. 
  • Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: three case studies and a review of the literature. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Cerebrospinal fluid protein elevation secondary to a subdural fluid collection in a child receiving multiple lumbar punctures. 
  • Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. 
  • Chemotherapy and radiation of anal canal cancer: the first approach. 
  • Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. 
  • Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. 
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic myelogenous leukemia. 
  • Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. 
  • Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. 
  • Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. 
  • Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. 
  • Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. 
  • Clinical management of adult ITP prior to splenectomy: a perspective. 
  • Clinical outcomes of older depressed patients with and without comorbid neuroticism. 
  • Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. 
  • Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. 
  • Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission. 
  • Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks. 
  • Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. 
  • Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. 
  • Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS. 
  • Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. 
  • Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. 
  • Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Complete Remission in the Nephrotic Syndrome Study Network. 
  • Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Complete remission seven years after treatment for metastatic malignant melanoma. 
  • Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. 
  • Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases. 
  • Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. 
  • Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. 
  • Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. 
  • Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. 
  • Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. 
  • Correlates of remission in primary care patients treated for minor depression. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. 
  • DSM melancholic features are unreliable predictors of ECT response: a CORE publication. 
  • Decreased Resting-State Activity in the Precuneus Is Associated With Depressive Episodes in Recurrent Depression. 
  • Detecting treatment-by-centre interaction in multi-centre clinical trials. 
  • Dialectical Behavior Therapy for Posttraumatic Stress Disorder (DBT-PTSD) Compared With Cognitive Processing Therapy (CPT) in Complex Presentations of PTSD in Women Survivors of Childhood Abuse: A Randomized Clinical Trial. 
  • Dietary and nutritional approaches for prevention and management of type 2 diabetes. 
  • Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. 
  • Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. 
  • Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. 
  • Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. 
  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. 
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. 
  • Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. 
  • Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. 
  • Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. 
  • Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. 
  • Editorial comment. 
  • Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. 
  • Effect of ureteral access sheath on stone-free rates in patients undergoing ureteroscopic management of renal calculi. 
  • Effectiveness of laparoscopic Roux-en-Y gastric bypass on obese class I type 2 diabetes mellitus patients. 
  • Effectiveness of psychological treatments for depression and alcohol use disorder delivered by community-based counsellors: two pragmatic randomised controlled trials within primary healthcare in Nepal. 
  • Effects of a right unilateral ultrabrief pulse electroconvulsive therapy course on health related quality of life in elderly depressed patients. 
  • Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. 
  • Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. 
  • Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. 
  • Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
  • Efficacy of second generation lithotriptors: a multicenter comparative study of 2,206 extracorporeal shock wave lithotripsy treatments with the Siemens Lithostar, Dornier HM4, Wolf Piezolith 2300, Direx Tripter X-1 and Breakstone lithotriptors. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. 
  • Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. 
  • Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. 
  • Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. 
  • Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. 
  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. 
  • Familial erythrophagocytic lymphohistiocytosis: late relapse despite continuous high-dose VP-16 chemotherapy. 
  • Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. 
  • Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. 
  • Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. 
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. 
  • Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. 
  • Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. 
  • Frontal white matter anisotropy and antidepressant remission in late-life depression. 
  • Functional outcomes in schizophrenia. 
  • Gastric Bypass Surgery Leads to Long-term Remission or Improvement of Type 2 Diabetes and Significant Decrease of Microvascular and Macrovascular Complications. 
  • Generalized anxiety disorder: acute and chronic treatment. 
  • Genetic lesions in diffuse large B-cell lymphomas. 
  • Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. 
  • Giant cell tumor of rib masquerading as thymoma: a diagnostic pitfall in needle core biopsy of the mediastinum. 
  • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 
  • Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. 
  • Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. 
  • Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. 
  • Granulocytic sarcoma in the absence of myeloid leukemia. 
  • HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group. 
  • HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. 
  • Has there been progress in the treatment of older patients with acute myeloid leukemia? 
  • Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia. 
  • High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. 
  • High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. 
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. 
  • High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • Hippocampus atrophy and the longitudinal course of late-life depression. 
  • Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. 
  • Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. 
  • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. 
  • Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. 
  • Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. 
  • Impact of symptoms of generalized anxiety disorder on the course of late-life depression. 
  • Impact of time duration after neoadjuvant therapy to surgery on response and outcome in rectal cancer patients. 
  • Impetiginous lesions in recurrent AML. 
  • Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia. 
  • Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. 
  • Inactive disease and remission in childhood-onset systemic lupus erythematosus. 
  • Income and attrition in the treatment of depression: a STAR*D report. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. 
  • Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. 
  • Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. 
  • Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. 
  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. 
  • Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. 
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. 
  • Is autologous stem cell transplantation still relevant for multiple myeloma? 
  • Is the appearance of the dextranomer/hyaluronic acid mound predictive of reflux resolution? 
  • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. 
  • Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. 
  • Laparoscopic myotomy for achalasia: predictors of successful outcome after 200 cases. 
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 
  • Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). 
  • Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. 
  • Long-term remission for disseminated Mycobacterium avium-intracellulare complex associated with antibody deficiency. 
  • Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). 
  • Longitudinal Cognitive Outcomes of Clinical Phenotypes of Late-Life Depression. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. 
  • Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. 
  • Management patterns of childhood-onset nephrotic syndrome. 
  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. 
  • Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. 
  • Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Metabolites and diabetes remission after weight loss. 
  • Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. 
  • Mind the Gap: Gaps in Antidepressant Treatment, Treatment Adjustments, and Outcomes among Patients in Routine HIV Care in a Multisite U.S. Clinical Cohort. 
  • Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. 
  • Moving Beyond Symptom Remission to Optimize Long-term Treatment of Attention-Deficit/Hyperactivity Disorder. 
  • Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). 
  • NCCN Practice Guidelines for Acute Myelogenous Leukemia. 
  • Naturalistic follow-up of youths treated for pediatric anxiety disorders. 
  • Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. 
  • Neural mechanisms of cognitive reappraisal in remitted major depressive disorder. 
  • Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. 
  • Nutritional basis of type 2 diabetes remission. 
  • Omalizumab use during pregnancy for CIU: a tertiary care experience. 
  • One-year change in anterior cingulate cortex white matter microstructure: relationship with late-life depression outcomes. 
  • Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. 
  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. 
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. 
  • Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. 
  • Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. 
  • P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. 
  • Partial response as a predictor of outcome in geriatric depression. 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. 
  • Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. 
  • Patients' perspectives on the definition of cure in chronic myeloid leukemia. 
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 
  • Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. 
  • Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. 
  • Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. 
  • Persistence and remission of musculoskeletal pain in community-dwelling older adults: results from the cardiovascular health study. 
  • Personality--life event congruence effects in late-life depression. 
  • Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. 
  • Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. 
  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. 
  • Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. 
  • Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. 
  • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. 
  • Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. 
  • Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Posttraumatic stress disorder in a national sample of female and male Vietnam veterans: risk factors, war-zone stressors, and resilience-recovery variables. 
  • Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer. 
  • Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. 
  • Predicting success in the endoscopic management of pediatric vesicoureteral reflux. 
  • Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. 
  • Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. 
  • Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • Predictors of recurrence in remitted late-life depression. 
  • Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. 
  • Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. 
  • Presence of neuroticism and antidepressant remission rates in late-life depression: results from the Neurobiology of Late-Life Depression (NBOLD) study. 
  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). 
  • Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. 
  • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. 
  • Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. 
  • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 
  • Progress against childhood cancer: the Pediatric Oncology Group experience. 
  • Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. 
  • Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Radiosurgical treatment for Ewing's sarcoma of the lumbar spine: case report. 
  • Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. 
  • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 
  • Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. 
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. 
  • Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). 
  • Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. 
  • Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 
  • Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. 
  • Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. 
  • Regression of extrafoveal choroidal osteoma following photodynamic therapy. 
  • Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? 
  • Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
  • Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. 
  • Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 
  • Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). 
  • Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. 
  • Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. 
  • Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR. 
  • Remissions in maternal depression and child psychopathology: a STAR*D-child report. 
  • Renal scarring and urinary tract infection after successful endoscopic correction of vesicoureteral reflux. 
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). 
  • Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. 
  • Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. 
  • Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. 
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy? 
  • Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. 
  • Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • SLC6A4 variation and citalopram response. 
  • Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? 
  • Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Sclerosing mesenteritis successfully treated with a TNF antagonist. 
  • Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. 
  • Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. 
  • Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. 
  • Shock wave lithotripsy of gallstones: results and 12-month follow-up in 174 patients. 
  • Spontaneous and treatment-induced cancer rejection in humans. 
  • Stereotactic radiotherapy for malignancies involving the trigeminal and facial nerves. 
  • Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. 
  • Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. 
  • Successful aneurysm resection and coronary artery revascularization following saphenous vein graft aneurysm rupture. 
  • Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. 
  • Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. 
  • Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. 
  • Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. 
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. 
  • The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. 
  • The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. 
  • The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. 
  • The course of depressive symptoms in older adults with comorbid major depression and dysthymia. 
  • The impact of diabetes on depression treatment outcomes. 
  • The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. 
  • The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. 
  • The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data. 
  • The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. 
  • The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. 
  • The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. 
  • The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. 
  • The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. 
  • Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. 
  • Therapeutic profile of the human glioma line D-54 MG in athymic mice. 
  • Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Thirty years of rectal cancer research: a brief history. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. 
  • Thymectomy for myasthenia gravis in older patients. 
  • Time-to-remission from geriatric depression: psychosocial and clinical factors. 
  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. 
  • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. 
  • Transient Reperfusion-Like Injury following Endovascular Treatment of Chronic Mesenteric Ischemia. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial. 
  • Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. 
  • Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. 
  • Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. 
  • Treatment of patients with pineoblastoma with high dose cyclophosphamide. 
  • Treatment of steroid-resistant nephrotic syndrome in the genomic era. 
  • Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. 
  • Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. 
  • Uncorrectable ptosis: primary cutaneous signet-ring cell carcinoma. 
  • Unrelated donor marrow transplantation in children. 
  • Update: vinorelbine (navelbine) in non-small cell lung cancer. 
  • Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. 
  • Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. 
  • Use of azathioprine in nine children with Crohn's disease. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. 
  • Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. 
  • Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas. 
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. 
  • Weight and Metabolic Outcomes 12 Years after Gastric Bypass. 
  • What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Routh, Jonathan Charles, Paul H. Sherman, M.D. Distinguished Associate Professor of Surgery, Pediatrics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Woodward, Julie Ann, Professor of Ophthalmology, Dermatology